A new specific drug target for primary effusion lymphoma (PEL) – an aggressive type of non-Hodgkin’s lymphoma – has been discovered by a team from the University of North Carolina, USA.
First author Jason Wong explains: “Patients with primary effu...
5 years ago
Antibiotic treatment helps inhibit the development of cutaneous T-cell lymphoma (CTCL), Danish researchers have reported.
The antibiotics, administered to treat Staphylococcus infection, were found to also result in a reduction in cytokines, which...
5 years ago
